Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)

• Egile Nagusiak: María Jesús Rubio (Egilea), María José Lecumberri (Egilea), Silvia Varela (Egilea), Jesús Alarcón (Egilea), María Eugenia Ortega (Egilea), Lydia Gaba (Egilea), Jaime Espinós (Egilea), Julia Calzas (Egilea), Pilar Barretina (Egilea), Isabel Ruiz (Egilea), Gloria Marquina (Egilea), Ana Santaballa (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2020-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-containing regimen/...